gms | German Medical Science

MAINZ//2011: 56. GMDS-Jahrestagung und 6. DGEpi-Jahrestagung

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V.
Deutsche Gesellschaft für Epidemiologie e. V.

26. - 29.09.2011 in Mainz

Serum 25-hydroxyvitamin D and risk of type 2 diabetes mellitus: Results from the MONICA/KORA Augsburg study

Meeting Abstract

  • Barbara Thorand - Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
  • Astrid Zierer - Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
  • Cornelia Huth - Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
  • Jakob Linseisen - Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
  • Christa Meisinger - Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
  • Michael Roden - Deutsches Diabetes Zentrum, Düsseldorf
  • Annette Peters - Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
  • Wolfgang Koenig - Universität Ulm, Ulm
  • Christian Herder - Deutsches Diabetes Zentrum, Düsseldorf

Mainz//2011. 56. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (gmds), 6. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi). Mainz, 26.-29.09.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11gmds169

doi: 10.3205/11gmds169, urn:nbn:de:0183-11gmds1698

Published: September 20, 2011

© 2011 Thorand et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Background: It has been suggested that vitamin D reduces the risk of type 2 diabetes mellitus (T2DM). Also 25-hydroxyvitamin D (25[OH]D) may have immunomodulatory effects and it is well established that subclinical inflammation increases the risk of T2DM. Therefore, the aim was to assess the association between serum 25[OH]D and T2DM development and to determine whether the effect of 25[OH]D on T2DM risk is mediated by subclinical inflammation.

Methods: Using a case-cohort design, baseline serum levels of 25[OH]D were measured in 231 male and 185 female cases with incident T2DM and 657 male and 610 female non-cases selected from a source population of 7,936 middle-aged participants in the population-based MONICA/KORA Augsburg studies. The mean follow-up time was 11.0 ± 4.7 years.

Results: After adjustment for age, sex, survey, season of blood sampling, lifestyle factors, parental history of diabetes and standard metabolic risk factors a significant inverse association was observed between serum 25[OH]D and incident T2DM. The hazard ratio (HR) and 95% confidence interval (CI) comparing tertile extremes was 0.63 (0.44-0.90); p-value for trend: 0.010. Further adjustment for C-reactive protein, interleukin-6, soluble intercellular adhesion molecule-1 (sICAM-1) and interferon inducible protein (IP-10)/CXCL10 attenuated the association (HR [95% CI]: 0.73 [0.50-1.05]; p-trend=0.090). Stratified analyses demonstrated a significant association between 25[OH]D and incident T2DM in younger women (<52 years), but not in older women (≥52 years). In men, the association tended to be more pronounced at an older age.

Conclusions: Our findings indicate that vitamin D status is inversely related to T2DM risk and that this association is only partially mediated by the effects of 25[OH]D on inflammation. Furthermore, our results suggest a modulating role of age and possibly hormone levels which needs to be clarified in further studies.